GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Capex-to-Operating-Income

Telix Pharmaceuticals (Telix Pharmaceuticals) Capex-to-Operating-Income : 0.17 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Telix Pharmaceuticals's Capital Expenditure for the six months ended in Dec. 2023 was $-5.21 Mil. Its Operating Income for the six months ended in Dec. 2023 was $31.34 Mil.

Hence, Telix Pharmaceuticals's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.17.


Telix Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Telix Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Capex-to-Operating-Income Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - - 0.28

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.17

Competitive Comparison of Telix Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Telix Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Capex-to-Operating-Income falls into.



Telix Pharmaceuticals Capex-to-Operating-Income Calculation

Telix Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-7.225) / 26.262
=0.28

Telix Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-5.211) / 31.344
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (OTCPK:TLPPF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Telix Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.